X4 Pharmaceuticals Inc
XFOR
NASDAQ
Biotechnology
$4.22
USD
-0.07 (-1.63%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $404.63M
Volume 840.9K
Revenue
$15.85M
TTM
-51.6%
YoY
Gross Margin
82%
TTM
-1.8%
YoY
Net Income
$-90.14M
TTM
+11.6%
YoY
Operating Cash Flow
$-83.74M
TTM
+23.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 2.0 | 1.8 | 2.6 | 2.7 | 8.8 |
YoY Growth | +250.4% | +215.2% | +79.1% | -90.6% | +346.3% |
Cost of Revenue | 0.3 | 0.4 | 0.4 | 0.6 | 1.6 |
Gross Profit | 1.6 | 1.4 | 2.2 | 2.1 | 7.2 |
Selling, General & Administrative | 9.5 | 11.6 | 7.4 | 7.0 | 8.5 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 27.9 | 28.9 | 25.9 | 22.4 | 23.6 |
Operating Income | -26.2 | -27.5 | -23.7 | -20.3 | -16.4 |
EBITDA | -25.9 | -27.3 | -23.5 | -20.1 | -15.4 |
Other Income / Expense | 2.1 | -1.0 | -0.0 | 0.1 | 0.4 |
Total Other Income / Expense | 0.5 | -2.3 | -0.2 | 0.1 | 0.2 |
Income Before Income Taxes | -25.7 | -29.8 | -23.9 | -20.2 | -16.2 |
Income Taxes | 0.0 | -0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -25.7 | -29.8 | -23.9 | -20.2 | -16.2 |
Consolidated Net Income / Loss | -25.7 | -29.8 | -23.9 | -20.2 | -16.2 |
Net Income Attributable to Common Shareholders | -25.7 | -29.8 | -23.9 | -20.2 | -16.2 |
Basic EPS | -$3.47 | -$0.69 | -$0.21 | -$0.16 | -$0.13 |
Diluted EPS | -$3.47 | -$0.69 | -$0.21 | -$0.16 | -$0.13 |
Basic Shares Outstanding | 7.4M | 43.3M | 111.6M | 126.3M | 126.3M |
Diluted Shares Outstanding | 7.4M | 43.3M | 111.6M | 126.3M | 126.3M |